Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CIDP: later-stage trial registry
5 of 5 indexed CIDP trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count
CIDP: 5 US clinical trials tracked, 5 recruiting.
CIDP is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 3 of these trials.
Enrollment posture brief
Registry condition cidp
OPEN 5 | RECR 100% | LATE 2 | EARLY 1 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
CIDP lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CIDP on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CIDP is recruiting above its size-band peers.
5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates CIDP research.
argenx accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical CIDP enrolment sits around 200 participants.
Median target enrolment is 200 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
CIDP splits between interventional and observational designs.
3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
NCT06920004
Biorepository and Registry for Plasma Exchange Patients
Charles M Knudson
NCT05004493
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
argenx
NCT07264426
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
NCT07091630
IVIG vs SCIG in CIDP
Rutgers, The State University of New Jersey
NCT05584631
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on CIDP records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CIDP trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CIDP page
5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 CIDP trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- argenx sponsors the most CIDP trials on record, review their full trial history before evaluating a specific study. See argenx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CIDP condition card totals 5 registered trials; most-linked intervention empasiprubart-placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.